The impact of the approval of prothrombin complex concentrates for vitamin K antagonist-related intracerebral hemorrhage: A retrospective study



      This study aimed to determine the impact of the approval of prothrombin complex concentrates on the treatment of vitamin K antagonist-related intracerebral hemorrhage.

      Materials and Methods

      We retrospectively studied all patients with vitamin K antagonist-related intracerebral hemorrhage treated with prothrombin complex concentrate at our institutes between January 2010 and June 2021. Before approval, prothrombin complex concentrate was administered as either 500 or 1000 IU at the physician's discretion (previous dose group). After approval, we adopted the manufacturer's recommended regimen (recommended dose group). The primary outcome was post-administration international normalized ratio. Secondary outcomes were the amount of prothrombin complex concentrate administered and proportion of post-administration international normalized ratio <1.5, hematoma expansion, thrombotic events within 30 days, modified Rankin scale 0–3 at discharge, and in-hospital mortality.


      Thirty-two and 19 patients in the previous and recommended dose groups, respectively, were included. The post-administration international normalized ratio significantly differed between groups. The prothrombin complex concentrate dose and proportion of patients achieving post-administration international normalized ratio <1.5 were significantly higher in the recommended dose group than in the previous dose group (1500 IU vs. 500 IU, p<0.001 and 100% vs. 68%, p = 0.008). The proportions of hematoma expansion, thromboembolic events, modified Rankin scale 0-3, and mortality did not differ between groups.


      After prothrombin complex concentrate approval, prothrombin time-international normalized ratio correction was more effective with a significant increase in the prothrombin complex concentrates dose for vitamin K antagonist-associated intracerebral hemorrhage; however, there was no apparent difference in clinical outcomes.

      Key Words


      VKA (vitamin K antagonist), ICH (intracerebral hemorrhage), pcc (prothrombin complex concentrate)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Schulman S.
        • Beyth R.J.
        • Kearon C.
        • et al.
        Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
        Chest. 2008; 133: 257S-298S
        • Lip G.Y.
        • Andreotti F.
        • Fauchier L.
        • et al.
        Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
        Europace. 2011; 13: 723-746
        • Flibotte J.J.
        • Hagan N.
        • O'Donnell J.
        • et al.
        Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.
        Neurology. 2004; 63: 1059-1064
        • Fang M.C.
        • Go A.S.
        • Chang Y.
        • et al.
        Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
        Am J Med. 2007; 120: 700-705
        • Yasaka M.
        • Minematsu K.
        • Naritomi H.
        • et al.
        Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin.
        Thromb Haemost. 2003; 89: 278-283
        • Hemphill J.C.
        • Greenberg S.M.
        • Anderson C.S.
        • et al.
        Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association.
        Stroke. 2015; 46 (3rd): 2032-2060
        • Steiner T.
        • Al-Shahi Salman R.
        • Beer R.
        • et al.
        European Stroke Organization (ESO) guidelines for the management of spontaneous intracerebral hemorrhage.
        Int J Stroke. 2014; 9: 840-855
        • Frontera J.A.
        • Lewin J.J.
        • Rabinstein A.A.
        • et al.
        Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine.
        Neurocrit Care. 2016; 24 (III): 6-46
        • Greenberg S.M.
        • Ziai W.C.
        • Cordonnier C.
        • et al.
        2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association.
        Stroke. 2022; 53: e282-e361
        • Yasaka M.
        • Sakata T.
        • Naritomi H.
        • et al.
        Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
        Thromb Res. 2005; 115: 455-459
        • Kwak R.
        • Kadoya S.
        • Suzuki T.
        Factors affecting the prognosis in thalamic hemorrhage.
        Stroke. 1983; 14: 493-500
        • Shoamanesh A.
        • Morotti A.
        • Romero J.M.
        • et al.
        Cerebral microbleeds and the effect of intensive blood pressure reduction on hematoma expansion and functional outcomes: a secondary analysis of the ATACH-2 randomized clinical trial.
        JAMA Neurol. 2018; 75: 850-859
        • Harrell F.E.
        Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis.
        springer, New York2001
        • Ovesen C.
        • Christensen A.F.
        • Krieger D.W.
        • et al.
        Time course of early postadmission hematoma expansion in spontaneous intracerebral hemorrhage.
        Stroke. 2014; 45: 994-999
        • Merchan C.
        • Ahuja T.
        • Raco V.
        • et al.
        High-dose s4-factor prothrombin complex concentrate for warfarin-induced intracranial hemorrhage.
        Neurohospitalist. 2020; 10: 16-21
        • Abdoellakhan R.A.
        • Miah I.P.
        • Khorsand N.
        • et al.
        Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis.
        Neurocrit Care. 2017; 26: 64-69
        • Leissinger C.A.
        • Blatt P.M.
        • Hoots W.K.
        • et al.
        Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.
        Am J Hematol. 2008; 83: 137-143
        • Goldstein J.N.
        • Refaai M.A.
        • Jr M.T.J.
        • et al.
        Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial.
        Lancet. 2015; 385: 2077-2087
        • Milling Jr, T.J.
        • Refaai M.A.
        • Goldstein J.N.
        • et al.
        Thromboembolic events after vitamin k antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies.
        Ann Emerg Med. 2016; 67: 96-105
        • Kawamata T.
        • Takeshita M.
        • Kubo O.
        • et al.
        Management of intracranial hemorrhage associated with anticoagulant therapy.
        Surg Neurol. 1995; 44 (discussion 443): 438-442